ROLE OF BRAIN NATRIURETIC PEPTIDE IN DIAGNOSING HEART FAILURE IN PATIENTS ON PROGRAM HEMODIALYSIS
https://doi.org/10.24884/1561-6274-2006-10-2-38-41
Abstract
THE AIM of the investigation was to study possible usage of brain natriuretic peptide (BNP) in diagnostics of chronic heart failure (CHF) in patients with chronic kidney disease (CKD) treated by chronic hemodialysis. PATIENTS AND METHODS. Under observation there were 52 patients with CKD. Clinical-functional indices of CHF and BNP level were studied. RESULTS. The concentration of BNP in 77% of patients with clinico-laboratory signs of CHF was found to be reliably higher than that in patients without CHF. The BNP level was the higher the higher the stage of CHF. CONCLUSION. The data obtained have shown that the level of BNP 100 pg/ml and more can be used as a diagnostic criterion of CHF in CKD patients treated by chronic hemodialysis.
About the Author
O. E. Ilyicheva
Челябинская государственная медицинская академия
Russian Federation
Russian Federation
References
1. Бикбов БТ, Томилина НА. О состоянии заместительной терапии больных с хронической недостаточностью в Российской Федерации в 2000 г (Отчет по данным Российского регистра). Нефрология и диализ 2002; 4(3): 148-170
2. Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999; 31 (9): 487-498
3. Oral I, Stejskal D, Loucky J et al. Impact of acute fluid restriction on levels of natriuretic peptides in patients on a chronic dialysis program. Vnitr Lek 2004; 50 (11): 812-817
4. Carr SJ, Bavanandan S, Fentum B. Prognostic potential of brain natriuretic peptide (BNP) in predialysis chronic kidney disease patients. Clin Sci (Lond)2005; 109 (1): 75-82
5. Safley DM, Awad A, Sullivan RA et al. Changes in B-type natriuretic peptide levels in hemodialysis and the effect of depressed left ventricular function. Adv Chronic Kidney Dis 2005; 12 (1): 117-124
6. Scbiller NB, Sbab PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-367
7. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458
8. Abergel Е, Tase М, Bohlader J. Which definition echocardiographic left ventricular hypertrophy? Am J Cardiol 1995; 75: 489-503
9. Canau A, Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodelling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-1558
10. Национальные рекомендации по диагностике и лечению ХСН (утвержденные съездом кардиологов РФ в октябре 2003 г.). Сердечная недостаточность 2003; 6: 276-297
11. Сторожаков ГИ,Томилина НА, Шило ВЮ, Гендлин ГЕ. Сердечная недостаточность у больных с хронической почечной недостаточностью. Сердечная недостаточность 2005; 5(3): 100-104
12. Dao Q, Krishnaswamy P, Kazanegra R et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379-385
13. Cowie M, Struthers A, Wood D еt al. Value of natriuretic peptides in assessment of patient with possible new heart failure in primary care. Lancet 1997; 350: 1349-1353
14. Bay M, Kirk V, Parner J et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003; 89: 150-154
Review
For citations:
Ilyicheva O.E. ROLE OF BRAIN NATRIURETIC PEPTIDE IN DIAGNOSING HEART FAILURE IN PATIENTS ON PROGRAM HEMODIALYSIS. Nephrology (Saint-Petersburg). 2006;10(2):38-41. (In Russ.) https://doi.org/10.24884/1561-6274-2006-10-2-38-41
Views:
471
Email this article 